Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison

BackgroundThe effectiveness of immune checkpoint inhibitors (ICIs) as adjuvant therapy for muscle-invasive urothelial carcinoma (MIUC) with high recurrence risk has been demonstrated. With no direct efficacy comparisons available, we aimed to indirectly compare the efficacy and safety of pembrolizum...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wei Chen, Soichiro Yoshida, Noriyoshi Miura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Oncology
Subjects:	adjuvant immunotherapy immune checkpoint inhibitor muscle-invasive urothelial carcinoma PD-1/PD-L1 inhibitor Shiny method
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1527540/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
by: Alexander D. Woods, MD, et al.
Published: (2025-03-01)

Clinical characteristics, diagnosis, treatment, and prognosis of Atezolizumab-induced encephalitis, aseptic meningitis or meningoencephalitis
by: Qingzi Yan, et al.
Published: (2025-01-01)

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors
by: Dandan Yuan, et al.
Published: (2025-12-01)

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study
by: Haiqing Zhao, et al.
Published: (2024-09-01)

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
by: Cecilia Olsson Ladjevardi, et al.
Published: (2024-11-01)

Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease
by: Ayaka Hayashi, et al.
Published: (2025-01-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01)

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
by: Yanan Zhao, et al.
Published: (2024-08-01)

The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors
by: Xin Y, et al.
Published: (2025-01-01)

Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective Observational Study by Using the Common Data Model
by: Seok Jun Park, et al.
Published: (2025-01-01)

A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report
by: Jingjing Chai, et al.
Published: (2025-02-01)

Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion
by: Yang Xia, et al.
Published: (2025-01-01)

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01)

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
by: Ting Yan, et al.
Published: (2025-01-01)

Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphoma
by: Rui Zhang, et al.
Published: (2025-01-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy
by: Meifeng Luo, et al.
Published: (2025-02-01)

Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer
by: Sung Uk Bae, et al.
Published: (2025-03-01)

Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients
by: Amalia Azzariti, et al.
Published: (2025-02-01)

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis
by: Huimin Zhao, et al.
Published: (2025-02-01)

Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1
by: Coco Duizer, et al.
Published: (2025-12-01)

Case report: A case of type 1 diabetes with diabetic ketoacidosis induced by envafolimab treatment in hepatocellular carcinoma
by: Youjia Li, et al.
Published: (2025-01-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)

Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development
by: Whi-An Kwon, et al.
Published: (2025-01-01)

Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis
by: Takafumi Yanagisawa, et al.
Published: (2025-02-01)

MODERN TREATMENT OF METASTATIC MELANOMA: FROM STANDARDS TO AN INDIVIDUALIZED APPROACH IN REAL CLINICAL PRACTICE
by: N. V. Zhukova, et al.
Published: (2018-06-01)

Uncovering the role of tumor cGAS expression in predicting response to PD-1/L1 inhibitors in non-small cell lung cancer
by: Yuichi Ozawa, et al.
Published: (2024-11-01)

Electrochemical sensors for the detection of immune checkpoint related proteins and their role in cancer companion diagnostics
by: Louise Barnaby, et al.
Published: (2025-03-01)

Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-α1 in advanced metastatic solid tumors: a multicenter Phase II clinical trial
by: Jiamin Yu, et al.
Published: (2025-02-01)

Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment
by: Tangyi Wang, et al.
Published: (2025-01-01)

Extraction, GC-MS analysis, cytotoxic, anti-inflammatory and anticancer potential of Cannabis sativa female flower; in vitro, in vivo and in silico
by: Waqas Safir, et al.
Published: (2025-02-01)

Infiltration of CD8+ cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma
by: Mengdi Fu, et al.
Published: (2025-02-01)

The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer
by: Vesna Ćeriman Krstić, et al.
Published: (2025-01-01)

Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives
by: Bujnak AC, et al.
Published: (2025-01-01)

Case report: Short-course hypofractionated radiation therapy combined with immune checkpoint inhibitors for the treatment of advanced ovarian mucinous cystadenocarcinoma
by: Xinan Wan, et al.
Published: (2025-01-01)

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01)

Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer
by: Huiping Qiang, et al.
Published: (2025-03-01)

Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer
by: Renate Pichler, et al.
Published: (2024-12-01)